e-drug
[Top] [All Lists]

[e-drug] DNDi on access to antimalarial ASAQ at net price

E-DRUG: DNDi on access to antimalarial ASAQ at net price
-----------------------------------------------------

Information from Sanofi-Aventis and DNDi on how to get access today to ASAQ at 
a 'No profit-No loss' price

To view this information in PDF, visit 
http://www.actwithasaq.org/en/ASAQAvailability_ENG_July2007

How to get access today to ASAQ at a 'No profit-No loss' price?

The artesunate plus amodiaquine antimalarial fixed-dose combination (ASAQ) is 
available as ArteSunate-AmodiaQuine Winthrop for public markets, NGOs and 
not-for-profit institutions, and under the brand names Coarsucam for the 
private market or Coarsucam Impact Malaria for 'no profit-no loss' social 
programs with the private sector.

In many countries, Coarsucam needs to be registered before ArteSunate 
AmodiaQuine Winthrop can be submitted to national regulatory agencies. 

Until Artesunate Amodiaquine Winthrop is registered, NGOs and other 
not-for-profit institutions who are interested in obtaining ASAQ can purchase 
Coarsucam Impact Malaria at a 'no profit-no loss' price under the following 
conditions:
- Coarsucam Impact Malaria is registered in the country of interest (AMM or 
authorisation of importation)
- Minimum order of 5000€
- Qualified person ('pharmacien responsable" or 'responsible pharmacist) 
required
- Storage facility available at country level

Coarsucam Impact Malaria was submitted for registration in 23 sub-Saharan 
African countries and is registered in the following countries as of 5 July 
2007 (this list will be updated regularly).

COUNTRIES: Date of approval
BURKINA FASO: 22 Dec 2006
CAMEROON: 2 July 2007
CENTRAL AFRICAN REPUBLIC: 3 July 2007
CHAD: 8 May 2007
CONGO: 24 Jan 2007
GABON: 30 Nov 2006
GUINEA: 27 Dec 2006
MALI: 17 Feb 2007
DEMOCRATIC REPUBLIC OF CONGO: 25 Jan 2007
GHANA: 27 Apr 2007
KENYA: 30 May 2007
MADAGASCAR: 20 Dec 2006
MAURITANIA: 14 Feb 2007

GMP inspection of the production site in Morocco was carried out by independent 
experts appointed by Medecins Sans Frontieres. The experts' report confirmed 
the compliance of ASAQ manufacturing operations with WHO GMP recommendations.

Information regarding the product
- Boxes of 25 blisters
- Product presentation with Summary of Product Characteristics (document 
available in English and in French) 

Contacts:
Sanofi-Aventis : 
Customer service Tel +33 1 41 24 01 34
Fax: + 33 1 41 24 58 62
francois.desbrandes@sanofi-aventis.com
claude.geant@sanofi-aventis.com
Medical Department: 
valerie.lameyre@sanofi-aventis.com

DNDi: Graciela Diap - gdiap@dndi.org

<Prev in Thread] Current Thread [Next in Thread>
  • [e-drug] DNDi on access to antimalarial ASAQ at net price, Ann-Marie Sevcsik <=